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There is an error in the fifth sentence of the Materials and methods section under the subheading "Inhibition of recombinant Transglutaminase activity". The correct sentence is: The two lyophilized TG2 inhibitors (see [Fig 1](#pone.0209522.g001){ref-type="fig"} for chemical structure) BJJF078 (3,4-Dimethoxy-N-(5-\[4-(acryloylamino)piperidine-1-sulfonyl\]-naphthalen-1-yl)-benzamide, see [S1 Appendix](#pone.0209522.s001){ref-type="supplementary-material"}, synthetized and provided by Covalab, Villeurbanne, France and Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Villeurbanne, France) and ERW1041E (2-\[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl\]-pyrrolidine-1---carboxylic acid quinolin-3-ylmethyl ester, kindly provided by Prof C. Khosla, Stanford University, USA) \[18, 22, 23\] were dissolved in DMSO (stock solution: 54 mM) and stored at -80°C.

![ERW1041E and BJJF078: Name and chemical structure of the TG2 inhibitors.](pone.0209522.g001){#pone.0209522.g001}

In [Fig 1](#pone.0209522.g001){ref-type="fig"}, the heading BJFF078 should be BJJF078. The authors have provided a corrected version here.
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